Literature DB >> 17545553

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.

Shinichi Toyooka, Hiroshi Date, Akiko Uchida, Katsuyuki Kiura, Minoru Takata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17545553     DOI： 10.1158/1078-0432.CCR-07-0070

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  9 in total

Review 1.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

Review 2.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Authors:  Kim-Son H Nguyen; Susumu Kobayashi; Daniel B Costa
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

3.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Authors:  Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2016-03-15

4.  Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.

Authors:  Jikai Zhao; Jinchen Shao; Ruiying Zhao; Rong Li; Keke Yu; Lei Zhu; Jie Zhang
Journal:  Thorac Cancer       Date:  2017-11-09       Impact factor: 3.500

5.  Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.

Authors:  A K M Azad; Alfons Lawen; Jonathan M Keith
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

6.  De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.

Authors:  Yingying Ding; Hongliang Dong; YongCheng Li; Lei Liu; Ying Cai; Ying Wang; Shengya Tian; Chengtao Dai
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

Review 7.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

Review 8.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors.

Authors:  Lihua Huang; Liwu Fu
Journal:  Acta Pharm Sin B       Date:  2015-07-26       Impact factor: 11.413

Review 9.  [Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance 
in Lung Cancer].

Authors:  Qicheng Zhang; Ke Xu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.